ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses
2023/09/18
ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update
2023/08/31
ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners
2023/07/25
ADOCIA announces Q2 2023 financial results and a €10 million financing operation
2023/07/05
ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing
2023/06/01
Listing of ADOCIA shares suspended
2023/05/15
ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer
2023/04/25
ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities
2023/04/20
ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris
2023/03/15
ADOCIA announces its annual results for 2022 and provides corporate and financial update
2023/01/30
Adocia publishes its Letter to Shareholders
2022
Download
2022/12/21
ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023
2022/12/01
Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products
2022/10/25
ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates
2022/10/06
ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis
2022/10/03
ADOCIA: Upcoming investor meetings
2022/09/19
ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update
2022/09/15
ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th
2022/09/07
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes
2022/08/24
ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update
2022/06/23
Adocia publishes its Letter to Shareholders
2022/06/21
ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes
2022/06/16
ADOCIA confirms its eligibility for the PEA–PME
2022/05/20
ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris
2022/05/18
ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update
2022/05/18
ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao
2022/05/09
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao
2022/04/19
ADOCIA announces its annual results for 2021 and presents an update on activities
2022/04/11
ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao
2022/03/28
Adocia strengthens its cash position by 19 million euros following a real estate transaction
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2022/01/11
Number of shares and voting rights of ADOCIA as of December 31st, 2021
2022/01/06
ADOCIA announces its financial calendar for 2022
2021
Download
2021/12/20
ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022
2021/12/13
Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides
2021/10/26
Adocia announces 2021 third quarter financial results and a financing of €7 million
2021/10/14
ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China
2021/09/21
ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD
2021/09/10
Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021/09/07
ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities
2021/08/23
Number of shares and voting rights of ADOCIA as of July 31st, 2021
2021/07/29
Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2021/07/22
ADOCIA Announces Second Quarter 2021 Financial Results
2021/06/29
ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
2021/06/15
ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions
2021/06/08
ADOCIA confirms its eligibility for the PEA–PME
2021/06/02
ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021
2021/06/01
ADOCIA reinforces its board of directors with the appointment of three new independent members.
2021/05/26
ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
2021/05/11
ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021
2021/04/21
ADOCIA Announces the Release of its Universal Registration Document for the Year 2020
2021/04/21
ADOCIA Announces First Quarter 2021 Financial Results
2021/03/18
ADOCIA Announces Financial Results 2020 And Provides Corporate Update.
2021/03/10
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
2021/01/25
Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao
2021/01/11
Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes
2020
Download
2020/12/21
Adocia announces its financial calendar for 2021
2020/10/20
Adocia Announces Third Quarter 2020 Financial Results
2020/09/22
Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020
2020/09/15
Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes.
2020/09/07
September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event)
2020/09/03
September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD).
2020/08/18
Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019.
2020/07/30
Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S
2020/07/20
Adocia Announces First Half 2020 Financial Results
2020/06/08
Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience
2020/04/23
Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes
2020/04/23
Adocia announces the release of its Universal Reference Document for the year 2019
2020/04/20
Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon
2020/04/14
Adocia announces first quarter 2020 financial results and update on the impact of COVID-19
2020/03/12
Adocia Announces Full Year 2019 Financial Results
2019
Download
2019/12/17
Adocia announces its financial calendar for 2020
2019/12/11
Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners
2019/10/22
Adocia Announces Third Quarter 2019 Financial Results
2019/10/14
Adocia obtains additional financial resources to accelerate its growth
2019/09/30
Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case
2019/09/10
Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD
2019/08/23
Adocia announces the decision of the American Arbitration Association Tribunal
2019/07/17
Adocia Presents First Half 2019 Financial Results
2019/06/06
Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes
2019/06/04
Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions
2019/04/15
Adocia announces the release of its Reference Document for the year 2018
2019/04/15
Adocia announces first quarter 2019 financial results: cash position and revenue
2019/04/10
Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin
2019/04/10
Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris
2019/03/13
Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position
2019/02/12
Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019
2019/01/16
Adocia confirms its financial calendar for 2019
2019/01/03
PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas
2018
Download
2018/12/20
Adocia announces its financial calendar for 2019
2018/10/23
Adocia Announces Third Quarter 2018 Financial Results
2018/10/11
Adocia informs about a civil action filed by Eli Lilly
2018/10/05
Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon
2018/09/26
Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD)
2018/09/05
Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
2018/08/30
Adocia Announces Update to Second Arbitration Against Eli Lilly & Company
2018/08/21
Number of shares and voting rights of ADOCIA as of July 31, 2018
2018/08/08
American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly
2018/07/25
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2018/07/18
Adocia Presents First Half 2018 Financial Results
2018/06/14
Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions
2018/06/05
Adocia to Participate in the Jefferies 2018 Global Healthcare Conference
2018/06/01
Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine
2018/05/02
Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao
2018/04/26
Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China.
2018/04/19
Adocia announces the release of its Reference Document for the year 2017
2018/04/16
Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
2018/04/16
Adocia announces first quarter 2018 financial results: Cash position and revenue
2018/04/09
Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon
2018/03/19
ADOCIA announced its financial results for 2017 and its perspectives for 2018
2018/02/09
Adocia to Present at the 2018 BIO CEO & Investor Conference in New York
2018/02/06
Adocia Files Additional Arbitration Claims Against Eli Lilly & Company
2018/01/25
Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes
2018/01/08
Adocia announces its financial calendar for 2018
2018/01/04
Adocia announces expanded use of BioChaperone® beyond diabetes
2017
Download
2017/12/06
Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes
2017/11/20
Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study
2017/10/11
Adocia announces financial results for the third quarter 2017
2017/09/05
Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes
2017/07/26
Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer
2017/07/19
Adocia presents first half 2017 financial results
2017/06/07
Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes
2017/06/06
Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes
2017/06/01
Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump
2017/06/01
Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon
2017/05/30
Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions
2017/05/30
Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York
2017/05/19
Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris
2017/04/18
Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016
2017/04/18
Adocia announces first quarter 2017 financial results
2017/04/13
Number of shares and voting rights of Adocia as of March 31, 2017
2017/03/21
ADOCIA confirms its eligibility for the PEA – PME
2017/03/13
Number of shares and voting rights of ADOCIA as of February 28, 2017
2017/03/07
ADOCIA announced its financial results for 2016 and its perspectives for 2017
2017/02/14
Adocia announces its revenue and cash position for 2016
2017/02/13
Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference
2017/01/27
Adocia to hold conference call on Monday January 30, 2017
2017/01/27
Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro
2017/01/25
Adocia to hold conference call providing an update on its programs
2017/01/19
Adocia announces the transformation of its business model to increase the value of its projects
2017/01/05
Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes
2017/01/04
Adocia announces its financial calendar for 2017
2016
Download
2016/12/16
Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro
2016/11/10
Adocia to Participate in Upcoming Investor Conferences
2016/11/07
Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes
2016/10/27
Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
2016/10/12
Adocia announces third quarter 2016 financial results
2016/09/22
Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region
2016/09/20
Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes
2016/09/19
Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET)
2016/09/08
Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting
2016/09/07
Adocia announces new BioChaperone program combining a basal insulin and GLP-1s
2016/08/25
Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer
2016/07/20
Adocia presents first half 2016 financial results
2016/07/05
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2016/06/08
Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon
2016/06/06
Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions
2016/06/02
Adocia to Present at the Jefferies 2016 Global Healthcare Conference
2016/05/31
Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
2016/05/13
Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris
2016/05/03
Adocia strengthens its BioChaperone Combo patent portfolio
2016/04/27
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes
2016/04/14
Adocia announces first quarter 2016 results
2016/04/11
Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
2016/04/11
Adocia announces the release of its Reference Document, for the year 2015
2016/03/25
ADOCIA confirms its eligibility for the PEA – PME
2016/03/21
Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board
2016/03/16
Annual Financial Results 2015
2016/03/14
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
2016/02/16
ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015
2016/02/04
Adocia to Present at the 2016 Leerink Global Healthcare Conference
2016/01/29
Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
2016/01/08
Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets
2015
Download
2015/12/16
Adocia announces its financial calendar for 2016
2015/12/15
Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016
2015/12/11
Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100
2015/11/25
Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes
2015/11/19
Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region
2015/11/04
Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes
2015/10/13
ADOCIA Reports Third Quarter 2015 Financial Results
2015/10/06
Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy
2015/09/30
Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes
2015/08/27
Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
2015/07/21
Adocia presents financial results for the first half of 2015 highlighting strong growth
2015/07/10
Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
2015/06/26
Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
2015/06/15
Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices
2015/05/28
Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015
2015/05/26
Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA)
2015/05/04
Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014
2015/04/29
Adocia is now integrated into the EnterNext Tech 40 Index
2015/04/20
Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon
2015/04/14
Adocia announces first quarter 2015 results
2015/03/16
Adocia will present its 2014 annual results and its perspectives of growth during a conference call
2015/03/10
Adocia reports a strengthened cash position and intensifies clinical development
2015/03/05
Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly
2015/02/17
ADOCIA: annual revenue and net cash position for 2014
2015/02/10
Adocia: modification of the means allocated to the liquidity agreement
2015/02/05
Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet
2015/01/20
Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation
2015/01/09
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2014
Download
2014/12/29
ADOCIA announces its financial calendar for 2015
2014/12/22
ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow
2014/12/19
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry
2014/09/09
Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes
2014/08/25
Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer
2014/07/24
Adocia Reports Operational and Financial Results for the First Half of 2014
2014/07/09
Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes
2014/06/24
ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only)
2014/06/16
ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only)
2014/06/10
Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300
2014/06/04
Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014
2014/05/27
Adocia initiates ADR program in the United States
2014/05/20
Adocia: PR BC Lispro Initiation of phase 2a
2014/05/19
Adocia Press Release Liquidity Agreement with Kepler
2014/05/06
Termination of Liquidity Agreement with DSF Markets
2014/04/10
Adocia: Ultra Fast Lispro Clinical Results
2014/04/10
Adocia: Revenue Q1 2014
2014/03/26
Gerard Soula Interview – La bourse et la vie (Transcript)
2014/03/20
Adocia: Annual results 2013
2014/03/17
Adocia: confirmation of positive clinical results Combo
2014/02/26
Positive Clinical Results for Combo
2014/02/10
Adocia: Annual revenue of EUR 5.6 M in 2013
2014/01/28
Adocia strengthens its diabetic foot ulcer patent portfolio
2014/01/20
Half year report on Adocia’s liquidity agreement at December 2013
2014/01/06
Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin
2013
Download
2013/12/09
Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors
2013/11/13
Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog
2013/10/24
Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M
2013/10/19
Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère
2013/09/05
Activity and results for the first half of 2013
2013/07/29
Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration
2013/07/15
Half Year report on Adocia’s Liquidity agreement with BIL Finance
2013/04/26
Release of 2012 Reference Document (French only)
2013/04/24
Q1 2013 revenues
2013/04/23
Liquidity agreement
2013/04/23
PR Suspension liquidity agreement
2013/03/18
Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency
2013/02/13
ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012
2013/01/07
Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences
2012
Download
2012/10/30
Adocia announces the strong growth of its turnover
2012/10/22
Adocia is extending its intellectual property to new formulations of monoclonal antibodies
2012/10/01
EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany
2012/09/12
Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde
2012/09/07
DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India
2012/09/03
Financial results and business report for the first half of 2012
2012/09/02
WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon
2012/06/13
Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment
2012/05/30
Additional contribution to Liquidity Agreement with Dexia Securities France (French only)
2012/04/26
ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012
2012/04/23
ADOCIA reports positive phase II clinical results
2012/04/02
Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA
2012/03/15
Liquidity agreement with Dexia Securities France (French only)
2012/03/15
ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial…
2023
Download
2023/09/18
ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update
2023/09/14
Number of shares and voting rights of ADOCIA as of August 31st, 2023
2023/09/13
ADOCIA Announces the Availability of a Prospectus for the Admission to Trading of Shares Issued or likely to be Issued to IPF Partners on Exercise of its Warrants
2023/08/31
ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners
2023/08/30
Number of shares and voting rights of ADOCIA as of July 31st, 2023
2023/07/31
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2023/07/27
ADOCIA Announces the Availability of a Prospectus for its Capital Increase and Convertible Bond Issue
2023/07/25
ADOCIA announces Q2 2023 financial results and a €10 million financing operation
2023/07/18
ADOCIA confirms its eligibility for the PEA–PME
2023/07/12
Number of shares and voting rights of ADOCIA as of June 30th, 2023
2023/07/05
ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing
2023/06/16
Number of shares and voting rights of ADOCIA as of May 31st, 2023
2023/06/01
Listing of ADOCIA shares suspended
2023/05/16
Number of shares and voting rights of ADOCIA as of April 30th, 2023
2023/05/15
ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer
2023/04/27
ADOCIA Announces the Release of its Universal Registration Document for the Year 2022
2023/04/25
ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities
2023/04/20
ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris
2023/04/13
Number of shares and voting rights of ADOCIA as of March 31st, 2023
2023/03/17
Number of shares and voting rights of ADOCIA as of February 28th, 2023
2023/03/15
ADOCIA announces its annual results for 2022 and provides corporate and financial update
2023/02/15
Number of shares and voting rights of ADOCIA as of January 31st, 2023
2023/01/30
Adocia publishes its Letter to Shareholders
2023/01/23
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2023/01/16
Number of shares and voting rights of ADOCIA as of December 31st, 2022
2023/01/12
ADOCIA Announces its financial calendar for 2023
2022
Download
2022/12/29
ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao
2022/12/21
ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023
2022/12/15
Number of shares and voting rights of ADOCIA as of November 30th, 2022
2022/12/01
Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products
2022/11/16
Number of shares and voting rights of ADOCIA as of October 31st, 2022
2022/10/25
ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates
2022/10/13
Number of shares and voting rights of ADOCIA as of September 30th, 2022
2022/10/06
ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis
2022/10/03
ADOCIA: Upcoming investor meetings
2022/09/19
ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update
2022/09/15
ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th
2022/09/14
Number of shares and voting rights of ADOCIA as of August 31st, 2022
2022/09/07
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes
2022/08/25
Number of shares and voting rights of ADOCIA as of July 31st, 2022
2022/08/24
ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update
2022/07/20
Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2022/07/11
Number of shares and voting rights of ADOCIA as of June 30th, 2022
2022/06/23
Adocia publishes its Letter to Shareholders
2022/06/21
ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes
2022/06/16
ADOCIA confirms its eligibility for the PEA–PME
2022/06/14
Number of shares and voting rights of ADOCIA as of May 31st, 2022
2022/05/20
ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris
2022/05/18
ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update
2022/05/18
ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao
2022/05/13
Number of shares and voting rights of ADOCIA as of April 30th, 2022
2022/05/09
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao
2022/04/25
ADOCIA Announces the Release of its Universal Registration Document for the Year 2021
2022/04/19
ADOCIA announces its annual results for 2021 and presents an update on activities
2022/04/15
Number of shares and voting rights of ADOCIA as of March 31st, 2022
2022/03/28
Adocia strengthens its cash position by 19 million euros following a real estate transaction
2022/03/16
Number of shares and voting rights of ADOCIA as of February 28th, 2022
Number of shares and voting rights of ADOCIA as of January 31st, 2021
2022/01/13
ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2022/01/11
Number of shares and voting rights of ADOCIA as of December 31st, 2021
2022/01/06
ADOCIA announces its financial calendar for 2022
2021
Download
2021/12/20
ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022
2021/12/15
Number of shares and voting rights of ADOCIA as of November 30th, 2021
2021/11/19
Number of shares and voting rights of ADOCIA as of October 31st, 2021
2021/10/26
Adocia announces 2021 third quarter financial results and a financing of €7 million
2021/10/14
ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China
2021/10/12
Number of shares and voting rights of ADOCIA as of September 30th, 2021
2021/09/13
Number of shares and voting rights of ADOCIA as of August 31st, 2021
2021/09/10
Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021/09/07
ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities
2021/08/23
Number of shares and voting rights of ADOCIA as of July 31st, 2021
2021/07/29
Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2021/07/22
ADOCIA Announces Second Quarter 2021 Financial Results
2021/07/15
Number of shares and voting rights of ADOCIA as of June 30th, 2021
2021/06/15
ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions
2021/06/10
Number of shares and voting rights of ADOCIA as of May 31st, 2021
2021/06/08
ADOCIA confirms its eligibility for the PEA–PME
2021/06/01
ADOCIA reinforces its board of directors with the appointment of three new independent members.
2021/05/26
ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
2021/05/17
Number of shares and voting rights of ADOCIA as of April 30, 2021
2021/05/11
ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021
2021/04/21
ADOCIA Announces the Release of its Universal Registration Document for the Year 2020
2021/04/21
ADOCIA Announces First Quarter 2021 Financial Results
2021/04/19
ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021
2021/03/18
ADOCIA Announces Financial Results 2020 And Provides Corporate Update.
2021/03/17
Number of shares and voting rights of ADOCIA as of February 28th, 2021
2021/02/16
Number of shares and voting rights of ADOCIA as of January 31, 2021
2021/01/25
Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao
2021/01/20
Number of shares and voting rights of ADOCIA as of December 31, 2020
2021/01/18
Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2020
Download
2020/12/21
Adocia announces its financial calendar for 2021
2020/12/07
Number of shares and voting rights of ADOCIA as of November 30, 2020
2020/11/06
Number of shares and voting rights of ADOCIA as of October 31, 2020
2020/10/20
Adocia Announces Third Quarter 2020 Financial Results
2020/10/09
Number of shares and voting rights of ADOCIA as of September 30, 2020
2020/09/22
Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020
2020/09/08
Number of shares and voting rights of ADOCIA as of August 31, 2020
2020/09/07
September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event)
2020/08/25
Number of shares and voting rights of ADOCIA as of July 31, 2020
2020/08/18
Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019.
2020/07/20
Adocia Announces First Half 2020 Financial Results
2020/07/10
ADOCIA confirms its eligibility for the PEA – PME
2020/07/06
Number of shares and voting rights of ADOCIA as of June 30, 2020
2020/07/03
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2020/06/05
Number of shares and voting rights of ADOCIA as of May 31, 2020
2020/05/11
Number of shares and voting rights of ADOCIA as of April 30, 2020
2020/04/23
Adocia announces the release of its Universal Reference Document for the year 2019
2020/04/20
Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon
2020/04/14
Adocia announces first quarter 2020 financial results and update on the impact of COVID-19
2020/04/09
Number of shares and voting rights of ADOCIA as of March 31, 2020
2020/03/12
Adocia Announces Full Year 2019 Financial Results
2020/03/05
Number of shares and voting rights of ADOCIA as of February 28, 2020
2020/02/06
Number of shares and voting rights of ADOCIA as of January 31, 2019
2020/01/10
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2020/01/07
Number of shares and voting rights of ADOCIA as of December 31, 2019
2019
Download
2019/12/17
Adocia announces its financial calendar for 2020
2019/12/11
Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners
2019/12/06
Number of shares and voting rights of ADOCIA as of November 30, 2019
2019/11/07
Number of shares and voting rights of ADOCIA as of October 31st, 2019
2019/10/22
Adocia Announces Third Quarter 2019 Financial Results
2019/10/14
Adocia obtains additional financial resources to accelerate its growth
2019/10/04
Number of shares and voting rights of ADOCIA as of September 30, 2019
2019/09/30
Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case
2019/09/09
Number of shares and voting rights of ADOCIA as of August 31, 2019
2019/08/06
Number of shares and voting rights of ADOCIA as of July 31st 2019
2019/07/17
Adocia Presents First Half 2019 Financial Results
2019/07/11
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2019/07/05
Number of shares and voting rights of ADOCIA as of June 30, 2019
2019/06/11
Number of shares and voting rights of ADOCIA as of May 31, 2019
2019/05/07
Number of shares and voting rights of ADOCIA as of April 30, 2019
2019/04/15
Adocia announces the release of its Reference Document for the year 2018
2019/04/15
Adocia announces first quarter 2019 financial results: cash position and revenue
2019/04/10
Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris
2019/04/04
Number of shares and voting rights of ADOCIA as of March 31, 2019
2019/03/13
Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position
2019/03/08
Number of shares and voting rights of ADOCIA as of February 28, 2019
2019/02/12
Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019
2019/02/08
Number of shares and voting rights of ADOCIA as of January 31, 2019
2019/01/16
Adocia confirms its financial calendar for 2019
2019/01/10
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2019/01/10
Number of shares and voting rights of ADOCIA as of December 31, 2018
2018
Download
2018/12/20
Adocia announces its financial calendar for 2019
2018/12/06
Number of shares and voting rights of ADOCIA as of November 30, 2018
2018/11/07
Number of shares and voting rights of ADOCIA as of October 31, 2018
2018/10/23
Adocia Announces Third Quarter 2018 Financial Results
2018/10/05
Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon
2018/10/04
Number of shares and voting rights of ADOCIA as of September 30, 2018
2018/09/06
Number of shares and voting rights of ADOCIA as of August 31, 2018
2018/08/21
Number of shares and voting rights of ADOCIA as of July 31, 2018
2018/07/25
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2018/07/18
Adocia Presents First Half 2018 Financial Results
2018/07/04
Number of shares and voting rights of ADOCIA as of June 30, 2018
2018/06/08
Number of shares and voting rights of ADOCIA as of May, 31 2018
2018/05/07
Number of shares and voting rights of ADOCIA as of April, 30 2018
2018/04/19
Adocia announces the release of its Reference Document for the year 2017
2018/04/16
Number of shares and voting rights of ADOCIA as of March, 31 2018
2018/04/16
Adocia announces first quarter 2018 financial results: Cash position and revenue
2018/04/09
Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon
2018/03/19
ADOCIA announced its financial results for 2017 and its perspectives for 2018
2018/03/16
ADOCIA confirms its eligibility for the PEA – PME
2018/03/06
Number of shares and voting rights of ADOCIA as of February 28, 2018
2018/02/12
Number of shares and voting rights of ADOCIA as of January 31, 2018
2018/02/12
Adocia: additional resources allocated to the liquidity agreement
2018/01/10
Number of shares and voting rights of ADOCIA as of December 31, 2017
2018/01/09
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2018/01/08
Adocia announces its financial calendar for 2018
2017
Download
2017/12/07
Number of shares and voting rights of ADOCIA as of November 30, 2017
2017/11/08
Number of shares and voting rights of ADOCIA as of October 31, 2017
2017/10/12
Number of shares and voting rights of ADOCIA as of September 30, 2017
2017/10/11
Adocia announces financial results for the third quarter 2017
2017/09/18
Number of shares and voting rights of ADOCIA as of August 31, 2017
2017/07/19
Adocia presents first half 2017 financial results
2017/07/11
Number of shares and voting rights of ADOCIA as of June 30, 2017
2017/07/10
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2017/06/09
Number of shares and voting rights of ADOCIA as of May 31, 2017
2017/05/19
Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris
2017/04/18
Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016
2017/04/18
Adocia announces first quarter 2017 financial results
2017/04/13
Number of shares and voting rights of Adocia as of March 31, 2017
2017/03/21
ADOCIA confirms its eligibility for the PEA – PME
2017/03/13
Number of shares and voting rights of ADOCIA as of February 28, 2017
2017/03/07
ADOCIA announced its financial results for 2016 and its perspectives for 2017
2017/02/14
Adocia announces its revenue and cash position for 2016
2017/01/19
Adocia announces the transformation of its business model to increase the value of its projects
2017/01/06
Half year report on Adocia’s liquidity agreement with Kepler Chevreux
2017/01/04
Adocia announces its financial calendar for 2017
2016
Download
2016/10/12
Adocia announces third quarter 2016 financial results
2016/07/20
Adocia presents first half 2016 financial results
2016/05/13
Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris
2016/05/03
Adocia strengthens its BioChaperone Combo patent portfolio
2016/04/27
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes
2016/04/14
Adocia announces first quarter 2016 results
2016/04/11
Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
2016/04/11
Adocia announces the release of its Reference Document, for the year 2015
2016/03/21
Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board
2016/03/16
Annual Financial Results 2015
2016/02/16
ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015
2016/01/08
Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets
2015
Download
2015/12/16
Adocia announces its financial calendar for 2016
2015/12/15
Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016
2015/10/13
ADOCIA Reports Third Quarter 2015 Financial Results
2015/10/06
Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy
2015/10/05
Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon
2015/09/17
ADOCIA: additional contribution to the liquidity agreement
2015/07/21
Adocia presents financial results for the first half of 2015 highlighting strong growth
2015/07/07
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets
2015/06/15
Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices
2015/05/04
Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014
2015/04/20
Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon
2015/04/14
Adocia announces first quarter 2015 results
2015/03/16
Adocia will present its 2014 annual results and its perspectives of growth during a conference call
2015/03/10
Adocia reports a strengthened cash position and intensifies clinical development
2015/02/17
ADOCIA: annual revenue and net cash position for 2014
2015/02/10
Adocia: modification of the means allocated to the liquidity agreement
2015/01/09
Half year report on Adocia’s liquidity agreement with Kepler Capital Markets